Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 15601 - 15625 of 16010 in total
PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.
Investigational
Matched Description: … It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome. …
DG041 is a novel, first-in-class, orally-administered small molecule developmented for the prevention of arterial thrombosis and its complications. DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor for prostaglandins E2. EP3 is a target that associates with increased risk of various vascular...
Investigational
Matched Description: … DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor ... first-in-class, orally-administered small molecule developmented for the prevention of arterial thrombosis and
Tetraethylammonium is an experimental drug with no approved indication or marketed formulation. The only marketed drug containing tetraethylammonium was a combination drug called Fosglutamina B6, but this drug has now been discontinued. As an experimental agent, tetraethylammonium is used in its salt forms such as tetraethylammonium chloride and tetraethylammonium bromide....
Experimental
Investigational
Matched Description: … voltage- activated potassium channels, and nicotinic acetylcholine receptors. ... experimental agent, tetraethylammonium is used in its salt forms such as tetraethylammonium chloride and ... still being investigated, but it is known that tetraethylammonium blocks autonomic ganglia, calcium- and
M0002 is an orally-active selective vasopressin antagonist that inhibits water re-absorption from the kidneys. It is a vasopressin 2 antagonist and represents a new class of compounds – aquaretics – that produce profound diuresis without loss of electrolytes. It will be of major benefit to those patients not responding satisfactorily...
Investigational
Matched Description: … It is a vasopressin 2 antagonist and represents a new class of compounds – aquaretics – that produce …
Investigational
Experimental
4-Phenylfentanyl is a sythetic opioid derived from fentanyl. 4-Phenylfentanyl is around 8x the potency of fentanyl in analgesic tests on animals, but more complex 4-heteroaryl derivatives such as substituted thiophenes and thiazoles are more potent still, as they are closer bioisosteres to the 4-carbomethoxy group of carfentanil.
Illicit
Matched Description: … analgesic tests on animals, but more complex 4-heteroaryl derivatives such as substituted thiophenes and
Mevastatin or compactin is a cholesterol-lowering agent isolated from Penicillium citinium. It was the first discovered agent belonging to the class of cholesterol-lowering medications known as statins. During a search for antibiotic compounds produced by fungi in 1971, Akira Endo at Sankyo Co. (Japan) discovered a class of compounds that...
Experimental
Matched Description: … The compound was proposed to bind to the reductase enzyme and was named compactin. …
Piribedil has been investigated in Parkinson's Disease.
Investigational
Dipraglurant has been used in trials studying the treatment of Parkinson's Disease. It is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM).
Investigational
Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.
Investigational
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …
SRP 299 is a preparation of killed Mycobacterium vaccae that has been tested in uses related to inhibiting periodontal disease, in treating asthma and in treating eczema, itching and inflammation. Mycobacterium vaccae is a non-pathogenic, saprophytic bacteria whose antigens can be used to induce peripheral immune activation through the activity...
Investigational
Matched Description: … in treating eczema, itching and inflammation. ... Mycobacterium vaccae that has been tested in uses related to inhibiting periodontal disease, in treating asthma and
Investigational
Investigational
A non-aqueous co-solvent that serves as tool to study protein folding. It is also used in various pharmaceutical, chemical and engineering applications.
Experimental
Matched Description: … It is also used in various pharmaceutical, chemical and engineering applications. …
PRI-724 is under investigation in clinical trial NCT03620474 (Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis).
Investigational
Matched Description: … PRI-724 is under investigation in clinical trial NCT03620474 (Safety and Effectiveness of PRI-724 for …
Displaying drugs 15601 - 15625 of 16010 in total